Compare Pfizer Inc (PFE) vs Solstice Advanced Materials Inc. Common Stock (SOLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Solstice Advanced Materials Inc. Common Stock — how do they compare? Pfizer Inc trades at $29.57 (market cap $161.70B), while Solstice Advanced Materials Inc. Common Stock trades at $59.92 (market cap $9.68B). The key difference: Pfizer Inc is far larger — about 16.7× Solstice Advanced Materials Inc. Common Stock's market cap, and Pfizer Inc pays the higher dividend (6.06%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Solstice Advanced Materials Inc. Common Stock for 0 Days on average.
| PFE | SOLS | |
|---|---|---|
Market Cap | $161.70B | $9.68B |
Volume | 26,828,084 | 1,519,067 |
Sector | Health | Basic Materials |
52-Week High | $29.21 | $88.60 |
52-Week Low | $23.67 | $41.43 |
Typical Hold Time | 158 Days | 0 Days |
Enterprise Value | $213.20B | $11.35B |
Dividend Yield | 6.06% | 0.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.40, up 0.42% with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights Pfizer's focus on AI drug discovery and a catalyst-rich pipeline in obesity and oncology for 2026, while analysts maintain a mixed consensus with 40% buy ratings.
Pfizer presents a balanced opportunity with stable cash flows and dividend payments, but faces headwinds from patent cliffs and declining net income margins. The stock trades near analyst consensus targets with moderate upside potential, though execution risks in pipeline development and competitive pressures warrant caution for growth-oriented investors.
Solstice Advanced Materials (SOLS) trades at $60.91, up 0.33% with neutral technical signals. The company shows strong profitability with 30.64% gross margins and 14.95% ROE, though Q4 2025 earnings missed expectations. Recent developments include a $49M R&D expansion and termination of the Element Solutions merger, with the board authorizing a $500M share repurchase program. Analyst consensus is bullish with 80% buy ratings and a $80.22 price target representing 32% upside potential.
SOLS presents a compelling growth story with consistent earnings beats and institutional accumulation, though elevated P/E of 46.07 warrants caution. Key risks include execution challenges post-merger termination and margin pressure as profit margins declined from 6.09% to 5.12% year-over-year. The stock offers substantial upside if management delivers on growth initiatives while maintaining current profitability levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Solstice Advanced Materials Inc. Common Stock
Solstice Advanced Materials Inc. is a specialty materials company spun off from Honeywell in 2025, producing low-global-warming-potential refrigerants, blowing agents, and industrial solvents through its Refrigerants and Applied Solutions segment. Its Electronic and Specialty Materials segment supplies semiconductor materials, high-strength fibers, and healthcare-packaging films.
Read more on SOLS →
